Saturday 17 October 2026
Export ALKS’s income statement to Excel — free account
Alkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
41.22
1.12
+2.79%
Follow ALKS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 3.85% | 9.36% | 14.72% | 22.40% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
3 | 4 | 7 | 8 | |
| 1.99% | 4.82% | 10.64% | 15.11% | ||
ROIC |
2.76% | 4.36% | 31.75% | 36.01% | |
Return on Tangible Assets |
6.13% | 15.59% | 15.03% | 22.38% | |
Average Days of Receivables |
99.91 | 95.23 | 82.61 | 85.03 | |
Free Cash Flow per Share |
1.33 | 1.33 | 2.92 | 2.97 | |
Free Cash Flow |
222.71 | 221.18 | 481.42 | 490.91 | |
Capital Expenditures |
(28.47) | (35.02) | (39.33) | (50.17) | |
| Other line items | |||||
Cash ROIC |
5.61% | 5.86% | 15.34% | 17.26% | |
Accounts Receivable Turnover |
4.11 | 4.30 | 4.11 | 4.22 | |
Accounts Payable Turnover |
0.89 | 0.87 | 0.83 | 1.13 | |
Inventory Turnover |
1.05 | 0.80 | 1.04 | 1.11 | |
Average Days of Payables |
471.29 | 511.36 | 537.99 | 369.50 | |
Days of Inventory on Hand |
423.78 | 588.48 | 365.31 | 328.28 | |
Tax Rate |
(0.32) | (0.25) | (0.17) | (0.16) | |
Research and Development Expense of Revenue |
23.45% | 22.75% | 21.95% | 19.00% | |
Selling, General and Administrative Expense of Revenue |
50.44% | 50.85% | 47.53% | 43.47% | |
Share Based Compensation of Revenue |
7.10% | 7.18% | 6.69% | 6.13% | |
Interest Coverage |
2.04 | 5.12 | — | — | |
Operating CF/Net income |
3.80 | 1.68 | 2.15 | 1.60 | |
Depreciation/Fixed assets |
0.48 | 0.24 | 0.12 | 0.12 | |
Capex/Depreciation |
(0.27) | (0.67) | (1.45) | (1.66) | |
Revenue per Share |
9.98 | 9.40 | 8.96 | 9.22 | |
Operating CF per Share |
1.50 | 1.54 | 3.16 | 3.28 | |
Capex per Share |
(0.17) | (0.21) | (0.24) | (0.30) | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.03 |
Columns are period end dates